Objectives: The aims of this study were to compare 12-week outcomes of single-therapy tolterodine (Detrol LA) extended release to intravaginal estrogen (Estrace) for overactive bladder (OAB) symptoms and characterize 24-and 52-week outcomes in women undergoing combined therapy.
T he mainstays of treatment of women with overactive bladder (OAB) syndrome are pharmacotherapy and behavioral therapy. [1] [2] [3] Pharmacotherapy with antimuscarinic medications has demonstrated an overall 60% improvement for OAB symptoms. 4 In addition to anticholinergic therapy, the use of intravaginal estrogen to treat atrophy is sporadically used as part of an overall pharmacologic treatment plan. 5 Several studies have evaluated the role of estrogen in the treatment of urinary incontinence (UI), as well as the treatment of OAB symptoms. 5 The lower urinary tract shares a common embryologic origin with the lower genital tract and has been found to contain abundant estrogen receptors. Thus, an optimized estrogen milieu would be expected to have a beneficial effect on urinary tissue, symptoms, and function. 6 Although in general oral estrogen has not been noted to have a beneficial effect on UI symptoms, 7 intravaginal estrogen therapy has shown a more consistent benefit for lower urinary tract symptoms. Cardozo et al 8 performed a double-blind, placebo-controlled study of 110 women using intravaginal estradiol tablets for the treatment of lower urinary tract symptoms. A significant decrease in pretreatment sensory urinary urgency was demonstrated in the treatment group. A recent systematic review of the literature concluded that compared with placebo intravaginal estrogens improved urinary urgency, urinary frequency, stress, and urgency UI. 5 Limited data exist comparing treatment with anticholinergic therapy to intravaginal estrogen use for OAB symptoms. Our primary aim for this trial was to compare oral tolterodine extendedrelease formulation (Detrol LA; Pfizer, New York, NY) to lowdose intravaginal estradiol cream (0.1 mg estradiol per gram; Estrace vaginal cream; Warner Chilcott, Dublin, Ireland) using the reliable, valid, and responsive Overactive Bladder Questionnaire (OAB-q). 9 Secondary aims include evaluating Health-Related Quality of Life Questionnaire (HRQL) of the OAB-q, Patient Satisfaction Questionnaire (PSQ), Patient Global Impression of Improvement Questionnaire (PGI-I), voiding frequency, and UI episodes. In addition, we aimed to characterize long-term, 24-and 52-week, outcomes in women undergoing combined treatment.
MATERIALS AND METHODS
After institutional review board approval, women were recruited from the gynecology and urogynecology clinics and enrolled from April 2007 through July 2009. Participants provided written informed consent forms, and the study was registered on clinicaltrials.gov (NCT00465894).
Women with OAB symptoms were eligible for the study. Symptoms were assessed by questions related to patient bother on the OAB-q: "During the past 4 weeks, how bothered were you by (1) an uncomfortable urge to urinate, (2) a sudden urge to urinate with little or no warning, (3) accidental loss of small amounts of urine, (4) nighttime urination, (5) waking up at night because you had to urinate, (6) urine loss associated with a strong desire to urinate?" 9 Responses were given on a 6-point scale ranging from "not at all" to "a very great deal." Women answering "quite a bit" or greater severity on the OAB-q bother questions were considered to have OAB symptoms and were included in this study. Other inclusion criteria included menopausal for more than 12 months defined by having a prior bilateral oophorectomy or being 1 year from last period, or for women with hysterectomy and preserved ovaries, they must be 55 years or older or have a documented follicle-stimulating hormone level greater than 40 mIU/ mL. Women also had to be ambulatory, community dwelling, and able to participate in follow-up for the trial. Exclusion criteria included postvoid residual of more than 150 mL, glaucoma, hormone replacement therapy in the past 6 months, current anticholinergic therapy, breast cancer, impaired mental status, undiagnosed vaginal bleeding in the past 12 months, endometrial thickness on pelvic ultrasound of more than 5 mm, history of thromboembolic event, gynecologic cancer, untreated urinary tract infection, stage 3 pelvic organ prolapse or greater, recent diuretic medication change (1 month from change), neurological condition affecting bladder function (multiple sclerosis, Parkinson disease, spinal cord injury, spina bifida), congestive heart failure, prior pelvic irradiation, and interstitial cystitis.
At baseline, all participants underwent a physical examination and completed questionnaires including the OAB-q as well as a 3-day bladder diary. The first part of the OAB-q consists of 8 questions assessing symptom bother with a possible score from 0 to 100, with a higher score indicating greater symptom bother. The second part consists of 25 questions that assess HRQL addressing coping, concern, sleep, and social interaction where the scoring scale is from 0 to 100, with a higher score indicating a better quality of life. 9 Participants also completed the PGI-I and the PSQ after treatment. 10, 11 The PGI-I consists of a single question, "Circle the one response that best describes how your urinary tract condition is now, compared with how it was before you had treatment." There are 7 possible responses ranging from "very much better" to "very much worse." The PSQ consists of a single question, "How satisfied are you with your progress since your treatment? " in which the 3 possible responses are "completely satisfied," "somewhat satisfied," and "not satisfied." The bladder diary consisted of each woman completing a 3-day log of number of voids and number of urinary urgency incontinence episodes.
Women enrolled in the study and meeting inclusion criteria were randomized in a 1:1 ratio to treatment with either tolterodine extended-release 4-mg oral dose daily (Detrol LA; Pfizer) or lowdose estradiol topical cream 0.5 g applied vaginally each night for 6 weeks and then twice per week for the duration of the study (0.1 mg estradiol per gram; Estrace vaginal cream; Warner Chilcott). At 12 weeks, patients were offered addition of the alternative treatment regimen and were followed up prospectively. Randomization was performed using a permuted block randomization schedule with sealed envelopes. Compliance ("Are you taking your medication as prescribed?") and adverse effects were assessed by a telephone call at 4 weeks. Participants came with a bladder diary and were seen and reexamined at the primary outcome time point of 12 weeks and subsequently at 24 and 52 weeks, where only outcome questionnaires were completed. Clinical staff administering protocol questionnaires were blinded to treatment assignment. The 2-sample t test for analysis of the primary study outcome assessed change in symptom bother score between groups from baseline to 12 weeks. Changes in all outcome measures were calculated as the difference between 12-week and baseline scores (week 12 to baseline). Thus, a negative difference in severity scores indicates an improvement in patient-assessed bother. A sample size of 25 per group provided 80% power to detect a difference of 20 points or more at a 0.05 level of significance. For this determination, the SD of the change in severity scores was estimated to be 25 points based on prior study by Coyne et al. 9 We hypothesized a 20-point difference to be clinically meaningful because, on average, 20 was associated with a reduction of 3 or more voids per day 12 (however, subsequent to trial initiation, the minimally important difference was noted to be 10 points). 13 Analysis of the primary outcome was intention to treat. Bother scores at baseline and 12 weeks were compared using 2-sample t tests. At 12 weeks, subjects were offered addition of the alternative therapy with follow-up at 24 and 52 weeks utilizing the same outcome measures.
All secondary outcomes were compared between baseline and 12, 24, and 52 weeks using independent-sample t tests. We evaluated significance of changes in all scores from baseline to 12 weeks and 24-and 52-week follow-up within each group using paired t tests and Wilcoxon signed ranks tests. Comparisons of patient characteristics in the 2 study groups were conducted using the independent-samples t test for continuous measures and either the χ 2 tests of association or Fisher exact test for categorical measures. All hypothesis tests were evaluated at a 0.05 level of significance. Raw P values, unadjusted for multiple comparisons, are presented. SAS version 9.2 (SAS Institute Inc, Cary, NC) was used for all statistical analyses.
RESULTS
A total of 194 women were screened between April 2007 and July 2009, and of these, 58 were eligible and randomized. Thirty women were randomized to tolterodine and 28 to intravaginal estradiol cream. Twenty-five patients in the tolterodine group and 25 patients in the intravaginal estradiol group completed the 12-week study ( Fig. 1) .
Baseline demographics were similar for both groups including age, comorbidities, and current treatment with medications for bladder symptoms (Table 1 ). A significant difference in race was noted between groups with 13.3% African American in the tolterodine versus 39.3% in the intravaginal estradiol group, P = 0.02. There were no differences in baseline OAB-q symptom bother and HRQL scores, urgency incontinence episodes, or number of voids between groups at baseline ( Table 2) . Initial compliance was assessed at 4 weeks with a phone call from research staff, and 92.9% and 80% compliance was confirmed for the intravaginal estradiol cream and the tolterodine groups, respectively. At 12 weeks, there was no difference in symptom bother score (46.7 ± 23.4 vs 45.4 ± 21.0, P = 0.84) or magnitude of change (−20.6 ± 21.7 vs −15.8 ± 23.3, P = 0.45) between the tolterodine and intravaginal estradiol groups, respectively ( Table 2 ). There was a significant within-group decrease in symptom bother score from baseline to 12 weeks (tolterodine, P < 0.0001; intravaginal estradiol cream, P = 0.002) ( Table 2 and Fig. 2 ). There were no differences between groups on the OAB-q HRQL scale or bladder diary responses ( Table 2 ). The tolterodine group showed significant improvement in total quality of life including the subgroups of coping, concern, and sleep. The intravaginal estradiol group showed statistically significant improvement in total quality of life and in the subgroup for sleep ( Table 2 ). In addition, within-group analyses showed a statistically significant decrease in the median number of voids and UI episodes in the tolterodine group but not in the intravaginal estradiol group (Table 2 ). No differences in impression of improvement and satisfaction were noted between groups. There were no significant differences between the groups regarding estimated percentage of improvement and comfortability with continuation of their medication treatment (Table 3) . At 24 weeks, 28 of 58 patients on combined therapy completed follow-up. There were significant within-group changes of OAB-q bother score from baseline to 24 weeks in both the tolterodine + intravaginal estradiol (P < 0.0001) and intravaginal estradiol + tolterodine groups (P = 0.003) ( Table 4 ). Similar findings were noted for within-group changes at 52 weeks (Table 4 ). However, no difference was noted in change between groups at 24 and 52 weeks ( Table 4) .
Combined long-term therapy outcomes at 24 and 52 weeks were compared with single therapy at 12 weeks (Fig. 2 ). There was no significant within-group change in the OAB-q bother score from 12 to 24 weeks in the tolterodine + intravaginal estradiol group (−7.3 ± 14.7, P = 0.10); however, a significant improvement was noted in the intravaginal estradiol + tolterodine group (−20.0 ± 23.9, P = 0.008), with no difference noted between groups (P = 0.11). There were no significant changes noted in HRQL total or subscale scores in the tolterodine + intravaginal estradiol group, except in the concern subscale (P = 0.04); in the intravaginal estradiol + tolterodine group, there were significant changes noted in the total and all subscales (P ≤ 0.008), except social (P = 0.16). There were no significant between-group , P = 0.02), with no difference between groups (P = 0.10). There were no significant differences in the HRQL total or subscales within the tolterodine + intravaginal estradiol group (all P ≥ 0.15); in the intravaginal estradiol + tolterodine group, there was a significant change in HRQL total (13.3 ± 23.0, P = 0.04) and in the coping (18.2 ± 28.6, P = 0.03) and concern (17.7 ± 24.3, P = 0.01) subscales. There were no significant changes between groups (all P ≥ 0.10). At 24 and 52 weeks (n = 26), PSQ outcomes revealed that 88% and 84% of subjects, respectively, reported that they were "completely" or "somewhat satisfied," and 77% and 85% of subjects, respectively, reported that they were "much better" or "better" on the PGI-I.
Adverse events were recorded at 12, 24, and 52 weeks for all patients; however, at 52 weeks, the only adverse event reported was constipation, and the patient reporting had originally been in the tolterodine arm and added intravaginal estradiol at 12 weeks and stopped tolterodine at 24 weeks. No serious study-related adverse events were reported. Xerostomia, constipation, headache, gastroesophageal reflux, and mydriasis were the most commonly reported adverse effects at 12 weeks (Table 5 ). Fifty-six percent of patients in the tolterodine arm reported xerostomia, and 32% reported constipation. Interestingly, 20% of the patients in the intravaginal estradiol arm reported xerostomia as well. At 24 weeks, on combined therapy, the most common adverse effects reports were xerostomia and constipation.
DISCUSSION
This trial demonstrated that tolterodine and intravaginal estradiol both significantly improve symptom bother and HRQL in menopausal OAB patients and that there was no difference in the degree of improvement between the groups at 12 weeks. At the 12-week time point with the addition of the alternate therapy, within-group OAB symptom severity and HRQL scores remained improved significantly at 24 and 52 weeks from baseline. Interestingly, addition of tolterodine at 12 weeks to the intravaginal estradiol group resulted in further significant improvement in the OAB-q symptom bother score and the HRQL total and subscale scores above the single therapy effect noted at 12 weeks. These findings suggest that intravaginal estradiol therapy for OAB symptoms may for many women provide enough symptom relief, but if there is "still room for improvement," the addition of an antimuscarinic may provide additional benefit.
Additional secondary outcome measures characterized at 12 weeks included the number of voids and urgency UI episodes as recorded by a 3-day bladder diary. There were no differences noted between groups, but only the tolterodine group showed a significant decrease in number of voids and incontinence episodes at 12 weeks.
The use of intravaginal estrogen has previously been shown to decrease the incidence of urinary frequency and urgency in postmenopausal women. [14] [15] [16] One meta-analysis examining the effect of estrogen for the treatment of lower urinary tract symptoms demonstrated intravaginal estrogen therapy to be associated with a statistically significant improvement in frequency, nocturia, urgency, incontinence, bladder capacity, and first sensation to void. 17 The most recent meta-analysis was performed by the Cochrane group, which is a revised version from 2012. Overall, 34 trials were identified, including 19,676 incontinent women, Overall, there were approximately 1 to 2 fewer voids in 24 hours among women treated with intravaginal estrogen, and there were less frequency and urgency. 18 The potential theories of why estrogen therapy may improve the symptoms of overactive bladder include increasing the sensory threshold of the bladder, increasing αadrenergic receptor sensitivity in the urethral smooth muscle, promoting β3-adrenoreceptor-mediated relaxation of the detrusor muscle, and improving collagen quality and production in the perivesical and periurethral areas. 15, [19] [20] [21] Importantly, in this current study, significant OAB-q within-group changes in both symptom bother and HRQL subscales met the established 10-point minimally important difference. 13 This information was available subsequent to the information utilized for sample size requirements for this trial and suggests that measured changes that occurred were robust and meaningful. Limited data exist comparing the use of intravaginal estrogen to anticholinergic medication for OAB symptoms. Nelken et al 22 compared an estradiol vaginal ring versus oxybutynin for the treatment of OAB. The authors reported a significant decrease in voids per day in both groups but no significant difference between the groups. While our study did not demonstrate a significant decrease in voids in the intravaginal estradiol group, we feel that the subjective symptom impact to be a more important primary outcome because the ultimate measure of treatment success and likelihood of long-term compliance are intrinsically linked to the patient's perception of efficacy and symptom relief.
In our study, 63.6% of the women in the tolterodine group and 40.9% of the women in the intravaginal estradiol group reported that they requested additional treatment when asked at 12 weeks. To that end, an important issue to address was whether there would be benefit for concurrent therapy with intravaginal estrogen and an anticholinergic medication. There continue to be limited data examining this issue. Tseng et al 23 performed a randomized open-label trial of 80 women comparing a group treated with tolterodine alone to a group treated with tolterodine and intravaginal estrogen cream. The tolterodine plus intravaginal estrogen group had significant improvements in mean daytime frequency and volume voided after treatment but no significant difference in nocturia, urinary urgency, and urgency UI. 23 An additional open-label nonrandomized study compared women using tolterodine alone to women using tolterodine and intravaginal estrogen. There was no synergistic effect noted in this study. 24 In our study, women on combined therapy appeared to have an improved perception of symptom improvement as well as satisfaction. Larger more robust studies need to be conducted to assess any additive benefit of vaginal estrogen to anticholinergic or β-agonist treatment for OAB symptoms.
The significant limitation of this study is the lack of patient blinding with concomitant placebo use; however, the study was strengthened by clinician blinding, its randomized design, and the use of validated outcome measures. Furthermore, we unfortunately had significant attrition after 12 weeks as we included outcomes in the patients with complete data accrual.
Anticholinergic therapy is often discontinued because of common adverse effects of dry mouth, constipation, and blurry vision. 25 Given that our study demonstrated no differences for improvement in symptom bother and satisfaction between the groups, intravaginal estradiol therapy might be considered an effective and well-tolerated alternative to initial anticholinergic therapy for OAB symptoms in some women. It also suggests that if a synergistic benefit of vaginal estrogen therapy and anticholinergic medications is found, then this may result in improved compliance by allowing lower anticholinergic doses and thus a reduction in unwanted adverse effects. While inherent weaknesses in design are acknowledged, data from this study can be used to plan a larger double-blind, placebo-controlled trial to more robustly characterize the importance of intravaginal estrogen in optimizing the treatment of OAB symptoms.
